Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 486,110 shares. The offering, including the sale of the additional shares, is expected to close on June 17, 2013, subject to customary closing conditions. Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital.
Help employers find you! Check out all the jobs and post your resume.
